Pharmacokinetics of zidovudine in infants: A population analysis across studies

Although the use of zidovudine in newborns and infants has become standard therapy for prophylaxis and therapy of human immunodeficiency virus infection, the developmental pharmacology of zidovudine in the first months of life has not been fully described.

[1]  H. Mitsuya,et al.  Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides. , 1989, The New England journal of medicine.

[2]  S. Pelton,et al.  Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. , 1993, The Journal of pediatrics.

[3]  T F Blaschke,et al.  Potential of population pharmacokinetics to reduce the frequency of blood sampling required for estimating kinetic parameters in neonates. , 1992, Developmental pharmacology and therapeutics.

[4]  W. Parks,et al.  The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. , 1993, American journal of obstetrics and gynecology.

[5]  P. Krogstad,et al.  Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.

[6]  The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082) , 1994 .

[7]  S. Tadepalli,et al.  Radioimmunoassay for Retrovir, an anti-human immunodeficiency virus drug. , 1989, Journal of immunoassay.

[8]  B. Lacarelle,et al.  In vitro glucuronidation of 3'-azido-3'-deoxythymidine by human liver. Role of UDP-glucuronosyltransferase 2 form. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[9]  L. Mofenson,et al.  A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). , 1999, AIDS.

[10]  W. Parks,et al.  The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: Phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082) , 1993 .

[11]  Helmuth van Es,et al.  Glucuronidation of 3'-azido-3'-deoxythymidine in human liver microsomes: enzyme inhibition by drugs and steroid hormones. , 1992, Biochimica et biophysica acta.

[12]  R. Gelber,et al.  Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.